Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Drugs Gain Status Boost Within CDER

This article was originally published in The Pink Sheet Daily

Executive Summary

More than just a bureaucratic shell game, the promotion of the Office of Generic Drugs to “super office” status signals CDER Director Janet Woodcock’s tightened focus on generic drugs.

You may also be interested in...



US FDA Again Looks Outside Generic Drugs Office For New Director

Sally Choe, who has been working in the Office of Translational Sciences, will take over for Kathleen Uhl in March.

Gottlieb Promotes 'Team' Work For Product Reviews

US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.

CDER’s Drug Quality Office Separates Oversight Of ‘New’ And ‘Lifecycle’ Products

January launch of long-awaited Office of Pharmaceutical Quality is part of broader Center reorganization that also includes new Office of Study Integrity and Surveillance.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel